| Name | Title | Contact Details |
|---|
HudsonAlpha Institute seeks to expand the science of human genomics and hasten its movement into the marketplace where discoveries can benefit society.
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry`s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma`s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson`s Imbruvica, Astellas` and Pfizer`s Xtandi, Biogen`s Tysabri, Johnson & Johnson`s Tremfya, Gilead`s Trodelvy, Merck`s Januvia, Novartis` Promacta, Vertex`s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Aileron Therapeutics, based in Cambridge, Massachusetts, is a biopharmaceutical company developing and advancing a revolutionary class of drugs called Stapled Peptides. The company`s proprietary Stapled Peptides platform is a breakthrough approach to creating drugs for highly sought after biological targets using its novel peptide stabilizing technologies.
Bruker is a Goleta, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups.